CVS Health Proposes Four Ways To Cope With Gene Therapy Cost
As payers brace themselves for accelerated approvals of cell and gene therapies, they are searching for ways to manage those costs. In an effort to keep pace with competitors, CVS Health Corp. entered the fray, sketching out its strategy for delivering and covering gene therapy in the white paper “Gene Therapy, Keeping Costs From Negating Its Unprecedented Potential.”
There are 800 investigational new drug applications for cell and gene therapies, according to Sarah Butler Donovan, head of client solutions, marketing and operations at Avalere, and the FDA has had to hire 50 new reviewers that are going to be focusing on these new areas. “We’re anticipating, starting this year, roughly 10 approvals for cell and gene therapies a year,” Donovan said during a recent webinar.
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile
